Read more

February 11, 2022
1 min read
Save

Top in rheumatology: Booster guidance, vaccine uptake in people with inflammatory disease

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

The American College of Rheumatology has updated its recommendations regarding the COVID-19 vaccine for patients with rheumatic diseases.

The organization now recommends a fourth mRNA COVID-19 vaccine dose for patients on immunosuppressants and immunomodulatory therapy. This update in clinical guidance was the top story in rheumatology last week.

Source: Adobe.com
Source: Adobe Stock

Another top story covered data published in The Journal of Rheumatology that revealed greater COVID-19 vaccine uptake among patients with immune-mediated inflammatory disease compared with the general population.

Read these and more top stories in rheumatology below:

ACR recommends fourth dose of COVID-19 mRNA vaccine for patients on immunosuppressants

The American College of Rheumatology has updated its COVID-19 vaccine clinical guidance for patients with rheumatic diseases to recommend a fourth mRNA vaccine dose in patients receiving immunosuppressive or immunomodulatory therapy. Read more.

COVID-19 vaccine uptake higher among patients with IMIDs than general population

Approximately 83% to 88% of Canadian patients with immune-mediated inflammatory disease have received two doses of a COVID-19 vaccine, compared with 78% of the general population, according to data published in The Journal of Rheumatology. Read more.

'No clinically relevant effect': Duloxetine fails to impact chronic osteoarthritis pain

Adding duloxetine to usual care fails to result in any “clinically relevant effect” in patients with chronic hip or knee osteoarthritis pain, compared with usual care alone, according to data published in Arthritis & Rheumatology. Read more.

Nearly 1 in 6 patients with RA develop interstitial lung disease within 20 years

More than 15% of patients with rheumatoid arthritis develop interstitial lung disease within 20 years, with the latter condition associated with shorter survival, according to data published in Arthritis Care & Research. Read more.

Hooked on Rheum with Kenneth Saag, MD

As an undergrad, I studied bioengineering. When I started studying medicine, I found that the musculoskeletal system had the most in connection with my biomechanics interests. That is what initially attracted me to consider rheumatology, orthopedics and physical medicine and rehabilitation. Read more.